Paladin Advisory Group LLC Sells 126 Shares of Eli Lilly and Company $LLY

Paladin Advisory Group LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 28.4% in the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 317 shares of the company’s stock after selling 126 shares during the period. Paladin Advisory Group LLC’s holdings in Eli Lilly and Company were worth $247,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% in the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC raised its position in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the period. Covestor Ltd raised its position in Eli Lilly and Company by 24.9% during the first quarter. Covestor Ltd now owns 426 shares of the company’s stock valued at $352,000 after purchasing an additional 85 shares during the period. Kaufman Rossin Wealth LLC purchased a new stake in Eli Lilly and Company during the first quarter valued at approximately $242,000. Finally, Opes Wealth Management LLC raised its position in Eli Lilly and Company by 6.6% during the first quarter. Opes Wealth Management LLC now owns 337 shares of the company’s stock valued at $278,000 after purchasing an additional 21 shares during the period. Institutional investors own 82.53% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Guggenheim restated a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. Daiwa America cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Leerink Partnrs cut Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 7th. Finally, Daiwa Capital Markets cut Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $940.00.

Eli Lilly and Company Stock Up 2.3%

Shares of NYSE LLY opened at $927.48 on Thursday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a market capitalization of $876.82 billion, a PE ratio of 60.62, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The stock’s fifty day simple moving average is $792.03 and its two-hundred day simple moving average is $773.89. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $955.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The business had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter last year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 29.35%.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky acquired 1,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director J Erik Fyrwald acquired 1,565 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the acquisition, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 4,514 shares of company stock worth $2,894,841. Company insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.